Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | N82K |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | FGFR2 N82K lies within Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). N82K results in proliferation similar to wild-type Fgfr2 in a competition assay but increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 N82K |
Transcript | NM_000141.5 |
gDNA | chr10:g.121565568G>C |
cDNA | c.246C>G |
Protein | p.N82K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_022970.3 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_001320658.1 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_022970.4 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_001144917.2 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_001320658.2 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_001144917.1 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
NM_000141.5 | chr10:g.121565568G>C | c.246C>G | p.N82K | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 N82K | Advanced Solid Tumor | predicted - sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 N82K | Advanced Solid Tumor | predicted - sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 N82K | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 N82K | Advanced Solid Tumor | predicted - sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 N82K | Advanced Solid Tumor | predicted - sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 N82K | Advanced Solid Tumor | predicted - sensitive | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 N82K were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |